European Court Opens Door for Stem Cell Patenting
By GEN,
Genetic Engineering & Biotechnology News
| 12. 18. 2014
Today the European Court of Justice (CJEU) ruled that human embryonic stem cell patents could be allowed if organisms can't develop into human being. The decision overturns a 2011 European Union ruling that outlawed patents on hESC research, affirming that pluripotent human stem cells derived from parthoenogenetically activated oocytes can be patented in Europe.
Parthenogenesis refers to the initiation of embryogenesis without fertilization by oocyte activation in the absence of sperm though a variety of chemical and electrical techniques. The activated oocyte contains a single or double set of maternally derived chromosomes but does not contain paternal DNA.
While patents on hESC have been upheld in the United States, the European Patent Office (EPO) has refused to grant many of the same patents on ethical grounds if the commercial exploitation of those patents goes against public order or morality. Combined with a principle of noncommercialization of the human embryo, human body, and its products led Europe to deny the patentability of hESC.
Today’s judgment was precipitated though an appeal brought by International Stem Cell Corporation (ISC), a California-based biotechnology company...
Related Articles
By Hannah Thomasy, The Scientist | 03.15.2024
23andMe’s stock price since late 2020
23andMe, the first-off-the-blocks personal genomics company, has been struggling lately. In October, there were reports of a massive data breach focusing on 999,999 people with Ashkenazi heritage. The company eventually admitted that hackers had gained at least some access to 6.9 million profiles, and suggested that this was due to customers who had reused passwords. Even before news of the huge leak and the PR faux pas that followed, the company’s stock had...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...
By Tom Avril, The Philadelphia Inquirer | 02.08.2024
An 11-year-old deaf boy is now able to hear in one ear after undergoing a gene therapy treatment at Children’s Hospital of Philadelphia, one of the first such cases in the world. A second boy, aged 3, is scheduled...